IDEXX Laboratories, Inc. (IDXX)

How it makes money

IDEXX sells diagnostic instruments to clinics at a modest markup, then earns recurring, high-margin revenue for years afterward from the proprietary test kits, cartridges and software subscriptions each instrument requires — a classic razor-and-blade model. Reference laboratory testing and veterinary practice software add further recurring fees billed per test or per month. Because consumables and services, not the hardware itself, drive profitability, growth in the installed base of instruments compounds into growing recurring revenue over time.

Revenue by segment

Once a clinic buys an IDEXX analyzer, it is locked into IDEXX's own cartridges and consumables, since the machine will not run anyone else's; switching means replacing hardware, retraining staff and re-integrating practice software. That lock-in, repeated across tens of thousands of clinics worldwide, is why IDEXX keeps a majority of the North American in-clinic diagnostics market despite competition from Zoetis and Heska.

Pet ownership and the trend toward treating animals more like family members support steadily rising testing volumes, which held up well through past recessions. More recently, though, growth has slowed as fewer pet owners bring animals in for routine wellness visits, showing that demand is resilient but not entirely insulated from household budgets and vet-visit frequency.

Key risks

• Distributor inventory swings — A meaningful share of consumables reaches clinics through distributors, whose own purchasing and destocking decisions can push reported revenue above or below what end-user demand actually was in a given quarter.
• Competition from Covetrus and Zoetis — IDEXX's largest North American competitor, Covetrus, is simultaneously one of its distribution partners; Zoetis and others are also pushing into in-clinic diagnostics and practice software, pressuring the pricing and lock-in that support IDEXX's margins.
• Sensitivity to vet-visit frequency — Revenue growth depends on pet owners continuing to bring animals in for routine and wellness visits. A pullback in discretionary vet spending, as seen recently, slows testing volumes even though the installed base keeps growing.
• International and currency exposure — A significant share of sales is generated outside the United States, so currency movements and country-specific veterinary spending patterns can add volatility to reported results independent of underlying demand.

IDEXX sells to tens of thousands of independent veterinary clinics worldwide, both directly and through distributors such as Covetrus, so no single clinic customer is material; distributor inventory swings can still distort quarterly results.